CBO Remains Skeptical Of Rx Cost Savings In Medicare Estimates
Executive Summary
The Congressional Budget Office's baseline numbers for a prescription drug benefit should account for cost-savings achieved by preventative medicines, House Energy & Commerce/Health Subcommittee Chairman Bilirakis (R-Fla.) suggested during a May 16 hearing.
You may also be interested in...
Rx Cost-Saving Potential In Medicare Not Yet Demonstrated, CBO Says
Congressional Budget Office cost estimates for Medicare prescription drug proposals will continue to leave out any estimate of cost savings from expanded use of pharmaceuticals, CBO Director Douglas Holtz-Eakin suggested during an April 9 House Ways & Means Committee hearing
Rx Cost-Saving Potential In Medicare Not Yet Demonstrated, CBO Says
Congressional Budget Office cost estimates for Medicare prescription drug proposals will continue to leave out any estimate of cost savings from expanded use of pharmaceuticals, CBO Director Douglas Holtz-Eakin suggested during an April 9 House Ways & Means Committee hearing
Sales Rep Restrictions Contributing To Decline In Rx Spend At Wisconsin HMO
Dean Health System has experienced a decrease in overall pharmaceutical spend since restricting interactions between its physicians and manufacturer sales reps.